FTC Homeopathic Meeting Features Tort Attorney, Commissioner Critical Of Enforcement
This article was originally published in The Tan Sheet
The event agenda includes eight industry executives, researchers, attorneys and FDA officials who made presentations or were agency panel members at FDA’s public hearing in April. Commissioner Maureen Ohlhausen, who has advocated allowing firms regulatory room to advertise, speaks to open the meeting.
You may also be interested in...
CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. During a two-day public hearing, agency officials question stakeholders about trials, labeling and how well consumers understand their products.
The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.